Study on Sacituzumab Govitecan for Patients with Platinum-resistant Ovarian Cancer

Inclusion Criteria

• Have ovarian, fallopian tube, or primary peritoneal cancer that has returned or persisted after platinum-based treatment.
• Have a tumor that can be measured by scans or physical exams.
• Have a sample of the tumor available for testing.
• Be in good overall health with adequate blood cell counts and organ function.
• Be at least 18 years old.
• Have an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have recovered from any previous treatments or surgeries.
• Have received no more than two prior chemotherapy treatments for recurrent cancer.
• Women of childbearing potential must have a negative pregnancy test and agree to use contraception.
• Be at least two weeks past any previous treatments or high-dose steroids.
• Have signed an informed consent form agreeing to participate in the study.

Exclusion Criteria

• Women who are pregnant or breastfeeding.
• Have allergies to the study drug or its components.
• Require ongoing treatment with certain medications that interfere with the study drug.
• Have other medical or psychiatric conditions that could interfere with the study.
• Have had another invasive cancer within the last five years, except for certain skin or cervical cancers.
• Have significant heart disease or uncontrolled high blood pressure.
• Have severe lung disease or other serious medical conditions.
• Have active brain cancer or untreated brain metastases.
• Have uncontrolled seizures or active neurological disease.
• Have active infections like HIV, hepatitis B, or hepatitis C.
• Have a bleeding disorder or a history of significant bleeding.
• Have a large tumor mass over 7 cm, unless approved by the study investigator.
• Have severe digestive issues like nausea, vomiting, or intestinal blockage.
• Have had severe reactions to similar drugs in the past.